Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,004 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, Ngamprasertchai T, Batty EM, Cruz C, Callery JJ, Singh S, Saroj M, Kruabkontho V, Ngernseng T, Tanglakmankhong N, Tubprasert J, Abdad MY, Madmanee W, Kouhathong J, Suwannasin K, Pagornrat W, Piaraksa N, Hanboonkunupakarn P, Hanboonkunupakarn B, Poovorawan K, Potaporn M, Srisubat A, Loharjun B, Taylor WRJ, Chotivanich V, Chotivanich K, Imwong M, Pukrittayakamee S, Dondorp AM, Day NPJ, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. Schilling WHK, et al. Among authors: teixeira mm. Lancet Infect Dis. 2024 Jan;24(1):36-45. doi: 10.1016/S1473-3099(23)00493-0. Epub 2023 Sep 28. Lancet Infect Dis. 2024. PMID: 37778363 Free PMC article. Clinical Trial.
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV).
Jittamala P, Schilling WHK, Watson JA, Luvira V, Siripoon T, Ngamprasertchai T, Almeida PJ, Ekkapongpisit M, Cruz C, Callery JJ, Boyd S, Anunsittichai O, Hongsuwan M, Singhaboot Y, Pagornrat W, Tuntipaiboontana R, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Keayarsa S, Madmanee W, Aguiar RS, Santos FM, Batty EM, Hanboonkunupakarn P, Hanboonkunupakarn B, Sookprome S, Poovorawan K, Imwong M, Taylor WRJ, Chotivanich V, Sangketchon C, Ruksakul W, Chotivanich K, Pukrittayakamee S, Dondorp AM, Day NPJ, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. Jittamala P, et al. Among authors: teixeira mm. J Infect Dis. 2023 Nov 11;228(10):1318-1325. doi: 10.1093/infdis/jiad275. J Infect Dis. 2023. PMID: 37470445 Free PMC article. Clinical Trial.
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
Luvira V, Schilling WHK, Jittamala P, Watson JA, Boyd S, Siripoon T, Ngamprasertchai T, Almeida PJ, Ekkapongpisit M, Cruz C, Callery JJ, Singh S, Tuntipaiboontana R, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Keayarsa S, Madmanee W, Aguiar RS, Santos FM, Hanboonkunupakarn P, Hanboonkunupakarn B, Poovorawan K, Imwong M, Taylor WRJ, Chotivanich V, Chotivanich K, Pukrittayakamee S, Dondorp AM, Day NPJ, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. Luvira V, et al. Among authors: teixeira mm. BMC Infect Dis. 2024 Jan 15;24(1):89. doi: 10.1186/s12879-023-08835-3. BMC Infect Dis. 2024. PMID: 38225598 Free PMC article. Clinical Trial.
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
Wongnak P, Schilling WHK, Jittamala P, Boyd S, Luvira V, Siripoon T, Ngamprasertchai T, Batty EM, Singh S, Kouhathong J, Pagornrat W, Khanthagan P, Hanboonkunupakarn B, Poovorawan K, Mayxay M, Chotivanich K, Imwong M, Pukrittayakamee S, Ashley EA, Dondorp AM, Day NPJ, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ, Watson JA; PLATCOV Collaborative Group. Wongnak P, et al. Among authors: teixeira mm. Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00183-X. doi: 10.1016/S1473-3099(24)00183-X. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38677300 Free article.
SARS-CoV-2 Spillback to Wild Coatis in Sylvatic-Urban Hotspot, Brazil.
Stoffella-Dutra AG, de Campos BH, Bastos E Silva PH, Dias KL, da Silva Domingos IJ, Hemetrio NS, Xavier J, Iani F, Fonseca V, Giovanetti M, de Oliveira LC, Teixeira MM, Lobato ZIP, Ferreira HL, Arns CW, Durigon E, Drumond BP, Alcantara LCJ, de Carvalho MPN, de Souza Trindade G. Stoffella-Dutra AG, et al. Among authors: teixeira mm. Emerg Infect Dis. 2023 Mar;29(3):664-667. doi: 10.3201/eid2903.221339. Emerg Infect Dis. 2023. PMID: 36823719 Free PMC article.
The glycosaminoglycan-binding chemokine fragment CXCL9(74-103) reduces inflammation and tissue damage in mouse models of coronavirus infection.
Oliveira VLS, Queiroz-Junior CM, Hoorelbeke D, Santos FRDS, Chaves IM, Teixeira MM, Russo RC, Proost P, Costa VV, Struyf S, Amaral FA. Oliveira VLS, et al. Among authors: teixeira mm. Front Immunol. 2024 Apr 15;15:1378591. doi: 10.3389/fimmu.2024.1378591. eCollection 2024. Front Immunol. 2024. PMID: 38686377 Free PMC article.
A single dose of angiotensin-(1-7) resolves eosinophilic inflammation and protects the lungs from a secondary inflammatory challenge.
Magalhaes GS, Gregorio JF, Beltrami VA, Felix FB, Oliveira-Campos L, Bonilha CS, Righetti RF, Tibério IFLC, De Sousa FB, Rezende BM, Teixeira-Carvalho A, Santos RA, Campagnole-Santos MJ, Rodrigues-Machado MDG, Teixeira MM, Pinho V. Magalhaes GS, et al. Among authors: teixeira mm. Inflamm Res. 2024 Apr 24. doi: 10.1007/s00011-024-01880-x. Online ahead of print. Inflamm Res. 2024. PMID: 38656426
Epidemiological, clinical, and genomic landscape of coccidioidomycosis in northeastern Brazil.
Eulálio KD, Kollath DR, Martins LMS, Filho AD, Cavalcanti MDAS, Moreira LM, Tenório BG, Alves LGB, Yamauchi D, Barrozo LV, Thompson Iii GR, Nacher M, Stajich JE, Benard G, Bagagli E, Felipe MSS, Barker BM, Trilles L, Teixeira MM. Eulálio KD, et al. Among authors: teixeira mm. Nat Commun. 2024 Apr 12;15(1):3190. doi: 10.1038/s41467-024-47388-0. Nat Commun. 2024. PMID: 38609393 Free PMC article.
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review.
Papapetropoulos A, Topouzis S, Alexander SPH, Cortese-Krott M, Kendall DA, Martemyanov KA, Mauro C, Nagercoil N, Panettieri RA Jr, Patel HH, Schulz R, Stefanska B, Stephens GJ, Teixeira MM, Vergnolle N, Wang X, Ferdinandy P. Papapetropoulos A, et al. Among authors: teixeira mm. Br J Pharmacol. 2024 Jun;181(11):1553-1575. doi: 10.1111/bph.16337. Epub 2024 Mar 22. Br J Pharmacol. 2024. PMID: 38519837 Review.
1,004 results